🔴 Nasus Pharma is trading 5% down today after first-half net loss widened to $5.9 million

Nasus Pharma is trading at $3.46, down 5.08%, after investors reacted to its August 17, 2026 first-half results and business update, which showed net loss widening to $5.9 million from $1.3 million year over year.

• Research and development expenses increased to $2.6 million from $0.3 million.
• Cash, equivalents, and short-term deposits totaled $11.9 million.
• The company reported progress toward an NS002 pivotal study, while the broader healthcare rally is not supporting this company-specific decline.